The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
ApexOnco Front Page
Recent articles
10 December 2025
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
8 December 2025
Of 15 treatment-emergent adverse events, only one was deemed related to therapy.
8 December 2025
The company will try to get the Komzifti QTc prolongation warning removed.
8 December 2025
On efficacy, at least, BeOne’s BTK degrader shows an edge.
8 December 2025
The first stage of Preserve-003 shows a survival benefit in post-PD-(L)1 lung cancer – with caveats.
8 December 2025
It’s less about being fast, more about producing a better product.
5 December 2025
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.